Biotech startups, drug therapies, senolytics, and FDA approvals.
Human Longevity, Inc. has introduced a new clinical-grade whole genome sequencing product called Genomics for All, priced at $599. This test sequences an individual's entire DNA, providing AI-interpreted results via the HLI app without the need for a clinic visit. The service aims to enhance personal health insights and longevity strategies for users.
CND Life Sciences has successfully completed a growth financing round led by S-Curve Partners, with participation from existing investors. The funding will support the expansion of their Syn-One Test, a laboratory-developed test aimed at detecting abnormal phosphorylated alpha-synuclein and other markers associated with neurodegenerative diseases. This test has already been utilized by over 4,000 neurologists and healthcare professionals.
FibroBiologics has been granted a European patent for a gene therapy aimed at regenerating cartilage. The patent, EP 3043825 B1, includes 12 claims related to compositions that utilize expression vectors encoding therapeutic polynucleotides, such as Sox9, for cartilage repair. This development could have significant implications for individuals suffering from cartilage-related conditions.
XellSmart has announced that its allogeneic off-the-shelf iPSC-derived cell therapy, XS411, for Parkinson's disease has received Fast Track Designation from the US FDA. This designation allows for more intensive interactions with the FDA and eligibility for expedited review processes, potentially speeding up the development and approval of this innovative treatment.
Frontier Bio has made significant progress in a national $7 million competition organized by the NIH, focusing on the development of AI models that utilize human-cell models to accelerate testing for brain therapies. This advancement underscores the potential for AI to enhance research in longevity and regenerative medicine, particularly in understanding the aging process and developing effective treatments for age-related conditions.
Altimmune has commenced patient enrollment for the PERFORMA Phase 3 clinical trial to assess the safety and efficacy of pemvidutide in treating metabolic dysfunction-associated steatohepatitis (MASH). Pemvidutide is a dual receptor agonist targeting glucagon and GLP-1 receptors, and it is also being studied for alcohol use disorder. This trial marks a significant step in addressing fatty liver disease, which is increasingly prevalent in the population.
4Moving Biotech has successfully completed enrollment for its Phase 2a clinical trial, INFLAM MOTION, which is investigating 4P004, a novel intra-articular GLP-1 receptor agonist. This trial aims to evaluate the drug's efficacy in addressing the inflammatory mechanisms that contribute to knee osteoarthritis symptoms and disease progression. A total of 129 patients from Europe and the United States have been enrolled in this randomized, double-blind, placebo-controlled study.
Niagen Bioscience has announced a collaboration with Evotec to advance the preclinical development of its rare disease drug, NB4168. This partnership will focus on conducting pharmacokinetic and pharmacodynamic studies to support the drug's progression towards human trials. The work will take place at Evotec's facility in Verona, Italy, marking a significant step in the drug development process.
Haut.AI has introduced a new Clinical Studies Software designed for skincare, beauty, ingredient, and dermatology organizations. This validated platform facilitates remote and hybrid clinical research by standardizing image capture and AI measurement across five workflow layers, quantifying 48 validated biomarkers related to skin health. The software aims to enhance the efficiency and accuracy of skin research.
ProMIS has released interim trial data suggesting a novel approach to targeting Alzheimer’s disease that may offer a safer alternative to existing therapies. Traditionally, treatments have focused on eliminating amyloid plaques in the brain, a strategy that has led to some approved medications but also significant side effects. This new approach could reshape the landscape of Alzheimer’s treatment and provide hope for more effective and tolerable options.
A recent study published in The Lancet indicates that D&D Pharmatech's drug, zabopegdutide, may provide therapeutic benefits for metabolic liver disease prior to any significant weight loss. This challenges the prevailing notion that weight loss is a prerequisite for improving liver health, suggesting that the drug may directly target liver function. The findings could reshape treatment strategies for metabolic-associated steatotic liver disease (MASH).
Generation Lab has launched the SystemAge test, an at-home diagnostic tool that measures biological aging with a focus on sex-specific insights. Unlike traditional tests that often provide a single composite score, SystemAge evaluates aging across 21 body systems, aiming to address the historical male bias in biological age assessments. This innovation could enhance personalized health optimization strategies for both men and women.
Genflow Biosciences Plc has made significant strides in its SIRT6 patent portfolio, particularly with the publication of a US patent application for a SIRT6 variant derived from centenarians. This variant shows potential for preventing and treating non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The United States Patent and Trademark Office (USPTO) has also granted prioritized examination for a foundational SIRT6 patent, signaling progress in this area of research.
Genflow has received fast-track examination status from the US Patent and Trademark Office for a key patent related to longevity gene therapy. This patent focuses on variants of the SIRT6 gene and aims to expand protections into muscular diseases such as frailty and sarcopenia. The expedited review could accelerate the development of therapies targeting age-related conditions.
